Zymeworks logo

Zymeworks

ZYME | NASDAQ
Chart Builder DCF Calculator
$26.45
+$0.21 (+0.80%)
At close: Nov 16, 2026, 4:00 PM ET
$26.45
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+0.80%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
50.6
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #275/1021 (Top 27%)

Key Statistics

Market Data

Market Cap $1.84B
1D Range
26.34 27.74
52W Range
21.81 31.46

Valuation (TTM)

PE 50.87
PB 7.13
EV/EBITDA 31.41

Valuation (NTM)

Forward PE 20.66
Forward PEG -0.17
Price Target $40.00
Loading financial charts...

Profile

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline f...

Sector Healthcare
Industry Biotechnology
Employees 231
IPO Date Apr 28, 2017
Fiscal Year January - December

Latest News

Zymeworks Announces $200 Million Share Repurchase Authorization

20 hours ago · globenewswire.com

Zymeworks Announces $200 Million Share Repurchase Authorization
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates

7 days ago · zacks.com

Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results

7 days ago · globenewswire.com

Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

19 days ago · zacks.com

Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

20 days ago · marketbeat.com

Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript

20 days ago · seekingalpha.com

Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

24 days ago · globenewswire.com

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

25 days ago · globenewswire.com

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

29 days ago · globenewswire.com

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

1 month ago · globenewswire.com

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Earnings

Latest Earnings
Nov 9, 2026
EPS
$2.28
Beat +0.44%
REV
$256.46M
Beat +12.78%
Next Earnings
Mar 1, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$40.00
Upside
+51.23%
Buy (11)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.